Geode Capital Management
CSTL icon

Geode Capital Management’s Castle Biosciences CSTL Stock Holding History

Geode Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.9M Buy
728,100
+13,187
+2% +$432K ﹤0.01% 2054
2025
Q4 		$27.8M Buy
714,913
+16,303
+2% +$526K ﹤0.01% 1835
2025
Q3 		$15.9M Buy
698,610
+8,684
+1% +$176K ﹤0.01% 2123
2025
Q2 		$14.1M Buy
689,926
+40,073
+6% +$742K ﹤0.01% 2142
2025
Q1 		$13M Buy
649,853
+21,657
+3% +$536K ﹤0.01% 2132
2024
Q4 		$16.7M Buy
628,196
+3,513
+0.6% +$107K ﹤0.01% 2062
2024
Q3 		$17.8M Buy
624,683
+7,004
+1% +$178K ﹤0.01% 2036
2024
Q2 		$13.4M Buy
617,679
+39,145
+7% +$872K ﹤0.01% 2148
2024
Q1 		$12.8M Buy
578,534
+12,419
+2% +$270K ﹤0.01% 2172
2023
Q4 		$12.2M Buy
566,115
+29,879
+6% +$526K ﹤0.01% 2223
2023
Q3 		$9.06M Buy
536,236
+38,552
+8% +$674K ﹤0.01% 2332
2023
Q2 		$6.83M Buy
497,684
+12,730
+3% +$258K ﹤0.01% 2525
2023
Q1 		$11M Buy
484,954
+19,287
+4% +$471K ﹤0.01% 2205
2022
Q4 		$11M Buy
465,667
+20,004
+4% +$464K ﹤0.01% 2205
2022
Q3 		$11.6M Buy
445,663
+15,107
+4% +$424K ﹤0.01% 2122
2022
Q2 		$9.45M Buy
430,556
+29,544
+7% +$687K ﹤0.01% 2290
2022
Q1 		$18M Buy
401,012
+15,271
+4% +$631K ﹤0.01% 1967
2021
Q4 		$16.5M Buy
385,741
+20,373
+6% +$1.06M ﹤0.01% 2087
2021
Q3 		$24.3M Buy
365,368
+25,293
+7% +$1.78M ﹤0.01% 1817
2021
Q2 		$24.9M Buy
340,075
+59,033
+21% +$3.9M ﹤0.01% 1817
2021
Q1 		$19.2M Buy
281,042
+48,005
+21% +$3.61M ﹤0.01% 1904
2020
Q4 		$15.6M Buy
233,037
+26,280
+13% +$1.42M ﹤0.01% 1876
2020
Q3 		$10.6M Buy
206,757
+94,912
+85% +$4.22M ﹤0.01% 1903
2020
Q2 		$4.21M Buy
111,845
+6,209
+6% +$212K ﹤0.01% 2432
2020
Q1 		$3.15M Buy
105,636
+46,901
+80% +$1.42M ﹤0.01% 2423
2019
Q4 		$2.02M Buy
58,735
+20,804
+55% +$509K ﹤0.01% 3004
2019
Q3 		$686K Buy
+37,931
New +$841K ﹤0.01% 3368

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management's CSTL Position: Q1 2026 in Review

Geode Capital Management increased its Castle Biosciences (CSTL) stake by 1.8% in Q1 2026, buying an estimated $432K and bringing the position to 728,100 shares worth $17.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2054.

Geode Capital Management first reported a position in CSTL in Q3 2019 and has held it in 27 quarters since. The position peaked at $27.8M in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Geode Capital Management held 728,100 shares of Castle Biosciences worth $17.9M as of Q1 2026.
  • Geode Capital Management bought 13,187 Castle Biosciences shares in Q1 2026, an estimated $432K.
  • Castle Biosciences made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #2054 holding.
  • Geode Capital Management first reported a position in Castle Biosciences in Q3 2019 and has held it in 27 quarters since.
  • Geode Capital Management's Castle Biosciences position peaked at $27.8M in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.